ABCL vs TFX · rev $12.4M vs P/E 2083, rev $1.12B
Abcellera Biologics Inc (ABCL) versus Teleflex Incorporated (TFX) — a side-by-side from cached financials, not a winner call.
Abcellera Biologics Inc (ABCL) is a biotechnology company listed on US.
Teleflex Incorporated (TFX) is a medical instruments & supplies company listed on NYSE.
Latest reported ABCL revenue for 2026-06-30 was $12.4M. Net income was -$98.6M. Revenue was up 48.7% from 2026-03-31 to 2026-06-30. ABCL currently screens at market cap $1.12B.
Latest reported TFX revenue for 2026-06-30 was $1.12B. Net income was $91.5M. TFX currently screens at market cap $5.53B and trailing P/E 2082.7.
ABCL currently screens at market cap $1.12B. TFX currently screens at market cap $5.53B and trailing P/E 2082.7.
Not investment advice. Open the ABCL and TFX stock pages for the full models.
Not investment advice.